FDA Approves Donidalorsen for Hereditary Angioedema | William Lumry, MD скачать в хорошем качестве

FDA Approves Donidalorsen for Hereditary Angioedema | William Lumry, MD

The FDA has approved donidalorsen (Dawnzera) — the first-ever RNA-targeted therapy for hereditary angioedema (HAE). In this interview with William Lumry, MD, founder of the Allergy & Asthma Specialists of Dallas, Lumry breaks down how this approval changes the landscape of HAE prevention. Learn how donidalorsen works as an antisense oligonucleotide that targets prekallikrein to prevent plasma kallikrein formation, offering patients a new mechanism of action and the possibility of every-8-week dosing. Dr. Lumry also discusses results from the OASIS-HAE and OASISplus trials, which showed up to a 96% reduction in HAE attacks and strong quality-of-life improvements. Watch to understand what this milestone means for clinicians and patients living with HAE. FDA Approval Date: August 21, 2025 Expert: William Lumry, MD – Allergy & Asthma Specialists of Dallas Therapy: Donidalorsen (Dawnzera) Key Highlights: 0:11: How donidalorsen differs from other prophylactic treatment for HAE 03:56: OASIS-HAE and OASISplus trial durability data #HAE #Donidalorsen #Dawnzera #FDAApproval #RNAtherapy #HereditaryAngioedema #RareDisease #OASISHAE #Allergy Immunology Read more: https://www.hcplive.com/view/fda-appr...